Ginkgo Bioworks Holdings Inc (DNA)
7.285
-1.32
(-15.29%)
USD |
NYSE |
Nov 14, 16:00
7.37
+0.08
(+1.17%)
After-Hours: 20:00
Ginkgo Bioworks Holdings Gross Profit Margin (Quarterly): 75.59% for June 30, 2024
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 75.59% |
| March 31, 2024 | 75.75% |
| December 31, 2023 | 80.98% |
| September 30, 2023 | 87.51% |
| June 30, 2023 | 77.54% |
| March 31, 2023 | 72.27% |
| December 31, 2022 | 69.25% |
| September 30, 2022 | 62.87% |
| Date | Value |
|---|---|
| June 30, 2022 | 55.81% |
| March 31, 2022 | 49.27% |
| December 31, 2021 | 55.16% |
| September 30, 2021 | 71.26% |
| June 30, 2021 | 60.79% |
| March 31, 2021 | 46.25% |
| December 31, 2020 | 56.82% |
| September 30, 2020 | 86.70% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
46.25%
Minimum
Mar 2021
87.51%
Maximum
Sep 2023
67.74%
Average
70.26%
Median
Gross Profit Margin (Quarterly) Benchmarks
| Boston Scientific Corp | 68.83% |
| UnitedHealth Group Inc | 21.56% |
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 84.00% |
| IGC Pharma Inc | 59.93% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -79.11% |
| Return on Assets | -48.84% |
| Return on Invested Capital | -79.11% |
| Profit Margin (Quarterly) | -386.4% |
| Operating Margin (Quarterly) | -281.1% |
| Return on Net Operating Assets | -125.7% |